Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Halberd Corp HALB

Halberd Corporation is a holding company. The Company is engaged in the acquisition vehicle for established businesses. It is also developing treatments for neurodegenerative diseases, such as post-traumatic stress disorder/chronic traumatic encephalopathy (PTSD/ CTE), Alzheimer’s disease and Parkinson’s disease. It has two issued patents and four provisional patent applications related to the extracorporeal treatment of blood-borne diseases and cerebrospinal fluid related diseases, with particular focus on the treatment and rapid detection of Covid-19 and other viruses. Its Sequential Dialysis Technique is a methodology that physically removes the pathophysiologic basis of the disease, eliminating it without side effects. The Company’s wholly owned subsidiary is Alaric Corporation.


OTCPK:HALB - Post by User

<< Previous
Bullboard Posts
Next >>
Post by AveragePennyon Mar 01, 2022 10:53am
50 Views
Post# 34471082

$HALB Halberd's COVID-19 Antibody is the Only One

$HALB Halberd's COVID-19 Antibody is the Only One

JACKSON CENTER, PA / ACCESSWIRE / March 1, 2022 / Halberd Corporation's (OTC PINK:HALB) previously developed SARS-CoV-2 antibody demonstrated superior binding capability to the SARS-CoV-2 Omicron variant disease antigen. The Halberd antibody was tested against monoclonal antibodies which are biosimilar to five FDA approved Emergency Use Authorization (EUA) COVID antibodies. The results are shown on the graph below.

On the vertical axis is the Absorbance (a measure of binding capability) of the various monoclonal antibodies (mAbs) to the Omicron variant disease antigen, and the antibody concentration (dose) is shown on the horizontal axis.

Halberd's antibody is depicted as 11D7, as highlighted on the graph. It reveals that with increased concentrations of the antibody, the binding capability increases. The other five (approved mAbs) have near zero binding, regardless of concentration.

https://www.accesswire.com/690803/halberds-covid-19-antibody-is-the-only-one-in-competitive-tests-to-bind-to-omicron-variant

<< Previous
Bullboard Posts
Next >>